Teclison, a clinical-stage biotechnology company developing innovative cancer therapeutics to induce tumor necrosis and enhance anti-tumor immunity, announced the completion of a $5.9 million in gross proceeds capital raise. The financing was led by W.T.T. Investment, the family office of Taiwan’s Tsai family, with participation from new and existing U.S. and Taiwan investors, including Nestor Capital.